Correlative Studies with Specimens from Multi-Site Trials (R01)

The summary for the Correlative Studies with Specimens from Multi-Site Trials (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Correlative Studies with Specimens from Multi-Site Trials (R01): -Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), is intended to support correlative studies by using tumor specimens collected during multi-institutional clinical trials. The Cancer Therapy Evaluation Program (CTEP), the Cancer Diagnosis Program (CDP), and the Cancer Biomarkers Research Group (CBRG), NCI, will cooperatively sponsor this funding opportunity with the following objectives: (1) to provide investigators with support for correlative studies using trial-related tumor specimens to compare genetic variations and molecular changes from the cell nucleus, the cytosol, and the cell surface and extracellular matrix to tumorigenesis and progression, drug resistance, therapeutic effectiveness of interventions, and patients' clinical outcomes; (2) to decipher mechanisms and to evaluate new cancer interventions by utilizing these tumor tissue resources and accumulated clinical trial results for better cancer risk assessment, early detection, and prediction of response to various cancer therapies and prevention strategies; and (3) to promote translational research and foster collaborations between basic researchers and clinical investigators from academia, private industry, and nonprofit organizations to ensure that new findings will be rapidly translated into clinical practice. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-296, that solicits applications under the Exploratory/Developmental Grant (R21) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.